NAVIGEN, INC. SBIR Phase I Award, September 2019
A SBIR Phase I contract was awarded to NAVIGEN, INC. in September, 2019 for $268,075.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.
All edits
SUMMARYInfluenzavirusinfectionisoneofthemostcommonacuterespiratorydiseasesandremainsoneofthelargestdiseaseburdensonhumanswithsevereprimaryviralpneumoniaoftenresultingindeathThepathogenicityofinfluenzaincludesahostresponsethatcanincludeaseveresystemicinflammatoryreactioncytokinestormandensuingvascularleakVascularleakisafundamentalelementinthepathogenesisofcirculatoryshockandmultipleorganfailurewhichcanleadtodeathininfluenzapatientsThelaboratoriesofDrDean Licofounder and former Chief Scientific Officer of Navigenand DrShannon Odelbergalong withNavigenhavedemonstratedthatvascularleakassociatedwithinflammationismediatedbyactivationofthesmall GTPaseARFa common nodal point in the signaling pathways of several inflammatory cytokines andgrowth factorsNavigen s objective is to reduce morbidity and mortality associated with influenza infections bymodifyingthishostresponseSpecificallyweproposetoevaluatetheefficacyofoursmallmoleculeARFinhibitorswiththehypothesisthatinhibitionofARFwillreducevascularleakelicitedbytheinfectionwhilehaving no adverse effect on immunitybased clearance of the virusNARRATIVEInfluenzainfectionremainsoneofthelargestdiseaseburdensonhumanswithsevereprimaryviralpneumoniaoftenresultingindeathThepathogenicityincludesahostresponsethatcanincludeaseveresystemicinflammatoryreactionandensuingvascularleakNavigenhasdemonstratedthatvascularleakassociated with inflammation is mediated by activation of the small GTPase ARFand proposes to evaluate itssmallmolecule ARFinhibitors in a mouse model of H Ninfection
NAVIGEN, INC. SBIR Phase I Award, September 2019
Find more entities like NAVIGEN, INC. SBIR Phase I Award, September 2019
